FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 07:19:18 28/05/2024 pm IST | ||
| 616.6 EUR | -7.53% |
|
| Current month | +6.66% | ||
| 1 month | +61.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 616.6 | -7.53% |
| 27/24/27 | 666.8 | +1.73% |
| 24/24/24 | 655.5 | +0.13% |
| 23/24/23 | 654.6 | +2.50% |
| 22/24/22 | 638.7 | +0.66% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 07:19 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD42D9 |
| ISIN | DE000SD42D93 |
| Date issued | 29/03/2021 |
| Strike | 183.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,167 € |
|---|---|
| Lowest since issue | 5.62 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- Certificat
